| Literature DB >> 32773946 |
Man Zhang1, Bende Zou2, Medha J Gunaratna1, Sahani Weerasekara1, Zongbo Tong1, Thi D T Nguyen1, Serkan Koldas1, William S Cao2, Conrado Pascual2, Xinmin Simon Xie2, Duy H Hua1.
Abstract
Neuropathic pain, epilepsy, insomnia, and tremor disorder may arrive from an increase of intracellular Ca2+ concentration through a dysfunction of T-type Ca2+ channels. Thus, T-type calcium channels could be a target in drug discovery for the treatments of neuropathic pain and epilepsy. From rational drug design approach, a group of 2,5-disubstituted 1,3,4-oxadiazole molecules was synthesized and their selective T-type channel inhibitions were evaluated. The synthetic strategy consists of a short sequence of three reactions: (i) condensation of thiosemicarbazide with acid chlorides; (ii) ring closing by 1,3-dibromo-5,5- dimethylhydantoin; and (iii) coupling with various acid chlorides. 5-Chloro-N-(5- phenyl-1,3,4-oxadiazol-2-yl)thiophene-2-carboxamide (11) was found to selectively inhibit T-type Ca2+ channel over Na+ and K+ channels in mouse dorsal root ganglion neurons and/or human embryonic kidney (HEK)-293 cells and to suppress seizure-induced death in mouse model. Consequently, compound 11 is a useful probe for investigation of physiologic and pathophysiologic roles of the T-channel, and provides a basis to develop a novel therapeutic to treat chronic neuropathic and inflammatory pains.Entities:
Year: 2019 PMID: 32773946 PMCID: PMC7413294 DOI: 10.3987/com-19-s(f)5
Source DB: PubMed Journal: Heterocycles ISSN: 0385-5414 Impact factor: 0.831